Clinical Trial

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

Study acronym: CBG
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 27, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-29; most recent amendment 2026-05-22.
Status change: Not Yet Recruiting → Recruiting 2024-09-20
Trial Details
NCT Number NCT06115603
Lead Sponsor University of Arkansas, Fayetteville
Conditions Attention-Deficit/Hyperactivity Disorder
Enrollment 76 participants
Start Date 2024-12-14
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-27